

October 6, 2020
Sawai Pharmaceutical Co., Ltd.

Sawai Receives Approval for Dutasteride Capsules

Osaka, Japan – October 5, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Dutasteride Capsules (the branded product: ZAGALLO®).

Dutasteride Capsules are prescribed for the treatment of male pattern alopecia.

The product approved by MHLW on October 5.

Product Name	Dutasteride Capsules ZA 0.5 mg [SAWAI]
Generic name:	Dutasteride
Brand products:	ZAGALLO® Capsules 0.5 mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

◆ Contact Information ◆

PR / IR Office, Sawai Pharmaceutical Co., Ltd.

E-mail : koho@sawai.co.jp